Skip to main content Accessibility help
×
Home

Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment

  • Jambur Ananth (a1) (a2), Kamala Aduri (a1), Sharath Parameswaran (a2) and Sarath Gunatilake (a2)

Abstract

Neuroleptic malignant syndrome (NMS) is associated with the administration of antipsychotic agents and other drugs such as l-dopa, antidepressants, and antihistaminic agents. Unexpected changes in mental status, new-onset catatonia, episodic tachycardia, tachypnea, hypertension, dysarthria, dysphagia, diaphoresis, sialorrhea, incontinence, low-grade temperature elevations, and rigidity should arouse suspicion. Several lines of evidence provide support for the involvement of dopamine. Most of the drugs implicated in NMS are D2 dopamine receptor antagonists. Central noradrenergic activity is also possibly related to the disorder, as sympathetic hyperactivity is associated with the active phase of NMS. Currently, the definitive role of GABA deficiency in NMS is yet to be established. Differential diagnosis should include malignant hyperthermia, lethal catatonia, lithium toxicity, serotonin syndrome, and heat stroke. A high degree of suspicion and the discontinuation of antipsychotic agents even if the diagnosis is not established are essential for the safety of the patient. Treatment of NMS should be individualized and be based empirically on the character, duration, and severity of the clinical signs and symptoms noted. The initial step in the treatment of NMS is the removal of the offending agent. Full-blown NMS is a serious condition and requires immediate supportive, nutritive, and electrolyte therapies. The administration of drugs that can improve NMS, such as IV dantrolene and/or oral bromocriptine, may also be taken into consideration, based on the severity and nature of the NMS.

Copyright

Corresponding author

Dr Jambur Ananth, Professor of Psychiatry, Department of Psychiatry, Harbor-UCLA Medical Center, 1000 West Carson Street, F-9, Torrance, CA 90502, USA. E-mail: jananth@dmhmsh.state.ca.us

References

Hide All
1.Delay, J, Pichot, P, Lemperiere, Tet al. Un neuroleptique majeur non phenothiazine et non reserpine, 1 ‘haloperidol, dans le traitement des psychoses [Haloperidol, a nonphenothiazine, nonreserpine neuroleptic for the treatment of psychosis]. Annales Med-Psychologiques 1960;118: 145152.
2.Khan, M, Farver, D. Recognition, assessment and management of neuroleptic malignant syndrome. S D J Med 2000;53(9):395400.
3.Keck, PE Jr, Pope, HG, McElroy, SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987;144: 13441366.
4.Bernardi, D, Amore, M, Keck, P Jret al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998;44: 748754.
5.Fawcett, J. How do we keep our eyes open? Psychiatric Ann 2000;30: 304.
6.Caroff, SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41: 7983.
7.Susman, VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72(4):325336.
8.Addonizio, G, Susman, VL, Roth, SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22: 10041020.
9.Shalev, A, Munitz, H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986;73: 337347.
10.Rosebush, P, Stewart, T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146: 717725.
11.Keck, PE, Pope, HG, McElroy, SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148: 880882.
12.Toru, M, Matsuda, O, Makiguchi, K, Sugano, K. Neuroleptic malignant syndrome-like state following a withdrawal of anti-parkinsonian drugs. J Nerv Ment Dis 1981;169: 324327.
13.Friedman, JH, Feinberg, SS, Feldman, RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 1985;254: 27922795.
14.Yamawaki, Y, Ogawa, N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. Intern Med 1992;31: 12981302.
15.Gordon, PH, Fruct, SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001;16(5):960974.
16.Ito, T, Shibata, K, Watanabe, Aet al. Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza: a encephalopathy. Eur J Pediatr 2001;160(6):401.
17.De Montigny, C, Cournoyer, G, Morissette, R, Langlois, R, Caille, G. Lithium carbonate addition in tricyclic anti-depressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40: 13271334.
18.Assion, HJ, Heinemann, F, Laux, G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci 1998;248: 231239.
19.Cohen, BM, Harris, PQ, Altesman, RLet al. Neuroleptic as well as an antidepressant? Am J Psychiatry 1982;139: 11651167.
20.Thornton, JE, Stahl, SM. Case report of tardive dyskinesia and parkinsonism associated with amoxapine therapy. Am J Psychiatry 1984;141(5):704705.
21.Lydiard, RB, Gelenberg, AJ. Amoxapine: an antidepressant with some neuroleptic properties? A review of its chemistry, animal pharmacology and toxicology, human pharmacology and clinical efficacy. Pharmacotherapy 1981;1: 163178.
22.Ansseau, M, Reynolds, CF III, Kupfer, DJet al. Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. J Clin Psychiatry 1986;47(6):320321.
23.Langlow, JR, Alarcon, RD. Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. J Clin Psychiatry 1989;50: 144145.
24.Madakasira, S. Amoxapine-induced neuroleptic malignant syndrome. Ann Pharmacother 1989;23: 5052.
25.Sumyoshi, A, Oguchi, T, Takahashi, Aet al. Two cases of syndrome malin induced by tricyclic antidepressants. Seishin Shinkeigaku Zasshi 1982;36: 461462.
26.June, R, Meraj, Y, Gossman, W. Neuroleptic malignant syndrome associated with nortriptyline. Am J Emerg Med 1999;17: 736737.
27.Aydin, N, Anac, E, Caykoylu, Aet al. Neuroleptic malignant syndrome due to citalopram overdose. Can J Psychiatry 2000;45(10):941942.
28.Baldessarini, RJ, Marsh, E. Fluoxetine and side effects. Arch Gen Psychiatry 1990;47: 191192.
29.Carter, CJ, Pycock, CJ. Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats [proceedings]. Br J Pharmacol 1977;60(2): 267P268P.
30.Corrigan, FM, Coulter, F. Neuroleptic malignant syndrome, amitriptyline and thioridazine. Biol Psychiatry 1988;23: 320321 .
31.Velamoor, VR. NMS complicated by diazepam. Br J Psychiatry 1992;160: 135136.
32.Menza, MA, Harris, D. Benzodiazepines and catatonia: an overview. Biol Psychiatry 1989;26(8):842846.
33.Larner, AJ, Smith, SC, Farmer, SF. ‘Non-neuroleptic malignant’ syndrome. J Neurol Neurosurg Psychiatry 1998;65(4):613.
34.Samson-Fang, L, Norlin, C. Intrathecal baclofen withdrawal simulating neuroleptic malignant syndrome in a child with cerebral palsy. Dev Med Child Neurol 2000;42(8):561565.
35.Park-Matsumoto, YC, Tazawa, T. Neuroleptic malignant syndrome associated with diphenhydramine and diprophyllin overdose in a depressed patient. J Neurol Sci 1999;162: 108109.
36.Chan-Tack, KM. Neuroleptic malignant syndrome due to promethazine. South Med J 1999;92: 10171018.
37.Ehara, H, Maegaki, Y, Takeshita, K. Neuroleptic malignant syndrome and methylphenidate. Pediatr Neurol 1998;19: 299301.
38.Edgar, J. Droperidol-induced neuroleptic malignant syndrome. Hosp Med 1999;60: 448450.
39.Nimmagadda, SR, Ryan, DH, Atkin, SL. Neuroleptic malignant syndrome after venlafaxine. Lancet 2000; 355(9200):289290.
40.Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988;24: 2529.
41.Lazarus, A, Mann, SC, Caroff, SN. The neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press, 1989.
42.Itoh, H, Ohtsuka, N, Ogita, Ket al. Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Seishin Shinkeigaku Zasshi 1977; 31: 565576.
43.Harsch, HH. Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. J Clin Psychiatry 1987;48: 328333.
44.Peloreno, AL, Levenson, JL, Pandurangi, AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1988;49(9):11631172.
45.Treloar, AJ, Crook, MA, Tuff, Pet al. Iron status, movement disorders, and acute phase response in elderly psychotic patients. J Neurol Neurosurg Psychiatry 1994;57: 208210.
46.Hermesh, H, Manor, I, Shiloh, Ret al. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 2002;22(3):252256.
47.Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77: 185202.
48.Levensen, JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142(10):11371145.
49.Ueda, M, Hamamoto, M, Nagayama, Het al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology 1999;52: 777781.
50.Akpaffiong, MJ, Ruiz, P. Neuroleptic malignant syndrome: a complication of neuroleptics and cocaine abuse. Psychiatr Q 1991;62: 299309.
51.Kosten, TR, Kleber, HD. Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse 1988;14: 335346.
52.Deuschl, G, Oepen, G, Hermle, L. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 1987;20: 168170.
53.Otani, K, Horiuchi, M, Kondo, Tet al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991;158: 850853.
54.Lazarus, AL, Moore, KE, Spinner, NB. Recurrent neuroleptic malignant syndrome associated with inv dup(15) and mental retardation. Clin Genet 1991;39: 6567.
55.Kawanishi, C, Furono, T, Onishi, Het al. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr Genet 2000;10(3):145147.
56.Ram, A, Cao, Q, Keck, PEet al. Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. Am J Med Genet 1995;60: 228230.
57.Suzuki, A, Kondo, T, Otani, Ket al. Association of TaqI A polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001;158: 17141716.
58.Kawanishi, C, Hanihara, T, Shimoda, Yet al. Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. Am J Psychiatry 1998;155: 12751277.
59.Kawanishi, C, Shimoda, Y, Fuzimaki, Jet al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 1998;160(1):102104.
60.Caroff, SN, Mann, SC, Lazarus, Aet al. Neuroleptic malignant syndrome: diagnostic issues. Psychiatric Ann 1991;21: 130147.
61.Moyes, DG. Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 1973;45: 11631164.
62.Boles, JM, Lecam, B, Mialon, P, Pennec, Y, Garre, M. Hyperthermie maligne des neuroleptiques: guérison rapide par le dantrolene. La Nouvelle Presse Medicale 1982;11: 674.
63.Yamawaki, S, Yano, E, Terakawa, Net al. On the results of a nationwide survey on neuroleptic malignant syndrome. Masui Sosei 1988;24(Suppl. 19):5267.
64.Yamawaki, S, Yano, E, Uchitomi, Yet al. Analysis of 497 cases of neuroleptic malignant syndrome in Japan. Masui Sosei 1990;26: 3544.
65.Peiris, DT, Kuruppuarachchi, K, Weerasena, LPet al. Neuroleptic malignant syndrome without fever: a report of three cases. J Neurol Neurosurg Psychiatry 2000;69(2):277278.
66.Haggarty, JM, Husni, M, Peat, Cet al. Atypical neuroleptic malignant syndrome? Can J Psychiatry 1999;44(7):711712.
67.Misiaszek, JJ, Potter, RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985;26: 6266.
68.Lee, JWY. Catatonic and non-catatonic neuroleptic malignant syndrome. Aust N Z J Psychiatry 2000;34(5): 877.
69.Mann, SC, Caroff, SN, Lazarus, A. Pathogenesis of neuroleptic malignant syndrome. Psychiatric Ann 1991;21: 175180.
70.Sakkas, P, Davis, JM, Janicak, PGet al. Drug treatment of neuroleptic malignant syndrome. Psychopharmacol Bull 1991;27: 381384.
71.Kapur, S, Zipursky, RB, Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156: 286293.
72.Greenberg, LB, Gujavarty, K. The neuroleptic malignant syndrome: review and report of three cases. Compr Psychiatry 1985;26: 6370.
73.Fink, M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry 1996;39: 14.
74.Tollefson, G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol 1982;2: 266270.
75.Miyatake, R, Iwanashi, K, Matsushita, Met al. No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated with malignant hyperthermia. J Neurol Sci 1996;143: 161165.
76.Feibel, JH, Schiffer, RB. Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: a case report. Am J Psychiatry 1981;138: 11151116.
77.Gurrera, RJ, Romero, J. Sympathoadrenomedullary activity in neuroleptic malignant syndrome. Biol Psychiatry 1992;32: 334343.
78.Gurrera, RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156: 169180.
79.Morris, HH III, McCormick, WF, Reinarz, JA. Neuroleptic malignant syndrome. Arch Neurol 1980;37: 462463.
80.Conlon, P. The spectrum concept of neuroleptic toxicity. Am J Psychiatry 1986;143: 811.
81.Dhib-Jalbut, S, Hesselbrock, R, Mouradian, MMet al. Bromocriptine treatment of neuroleptic malignant syndrome. J Clin Psychiatry 1987;48: 6973.
82.Price, DK, Turnbull, GJ, Gregory, RPet al. Neuroleptic malignant syndrome in a case of postpartum psychosis. Br J Psychiatry 1989;155: 849852.
83.Gurrera, RJ, Chang, SS. Thermoregulatory dysfunction in neuroleptic malignant syndrome. Biol Psychiatry 1996;39: 207212.
84.Kurlan, R, Hamill, R, Shoulson, I. Review: neuroleptic malignant syndrome. Clin Neuropharmacol 1984;7: 109120.
85.Goldwasser, HD, Hooper, JF, Spears, NM. Concomitant treatment of neuroleptic malignant syndrome and psychosis. Br J Psychiatry 1989;154: 102104.
86.Hoffman, WH, Chodoroff, G, Piggot, LR. Haloperidol and thyroid storm. Am J Psychiatry 1978;135: 484486 (correction, 135:762).
87.Schibuk, M, Schacter, D. A role for catecholamines in the pathogenesis of neuroleptic malignant syndrome. Can J Psychiatry 1986;31: 6669.
88.Murao, S, Ogawa, N, Ishibe, Yet al. Neuroleptic malignant syndrome associated with droxidopa in a patient with striatonigral degeneration. Res Com Psychol Psychiatry Behav 1993;18: 1318.
89.Keshavan, MS, Stecker, J, Kambhambati, RK. Creatinine kinase elevations with clozapine. Br J Psychiatry 1994;164: 118120.
90.Gurrera, R, Romero, J. Enzyme elevations in the neuroleptic malignant syndrome. Biol Psychiatry 1993;34: 634640.
91.Pappas, NJ Jr. Theoretical aspects of enzymes in diagnosis: why do serum enzymes change in hepatic, myocardial and other diseases? Clin Lab Med 1989;9: 595626.
92.Lew, TY, Tollefson, G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1983;18(12):14411446.
93.Kornhuber, J, Kornhuber, ME. Presynaptic dopaminergic modulation of cortisol input into the striatum. Life Sci 1986;39: 669674.
94.Weller, M, Kornhuber, J. A rationale for NMDA receptor antagonist therapy of neuroleptic malignant syndrome. Med Hypotheses 1992;38: 329333.
95.Frandsen, A, Schousboe, A. Dantrolene prevents glutamate cytotoxicity and Ca2+ release from intracellular stores in cultured cerebral cortical neurons. J Neurochem 1991;56: 10751078.
96.Osman, AA, Khurasani, MH. Lethal catatonia and neuroleptic malignant syndrome: a dopamine receptor shut-down hypothesis. Br J Psychiatry 1994;165: 548550.
97.Fink, M, Taylor, MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl. 1): 1/81/13.
98.Mann, SC, Caroff, SN, Bleir, HRet al. Lethal catatonia. Am J Psychiatry 1986;143: 13741381.
99.Northoff, G, Wenke, J, Pflug, B. Increase of serum creatinine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996;26: 547553.
100.Rosebush, PI, Mazurek, MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;338: 149151.
101.Castillo, E, Rubin, RT, Halsboer-Trachsler, E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989;146: 324328.
102.Francis, A, Divadeenam, K, Petrides, G. Advances in the diagnosis and treatment of catatonia. Convuls Ther 1997;12: 259.
103.Gurrera, RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002;25: 18311893.
104.Keck, PE Jr, Caroff, SN, McElroy, SL. Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy? J Neuropsychiatry Clin Neurosci 1995;7: 135144.
105.Schou, M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984;70: 594602.
106.Sansone, ME, Ziegler, DK. Lithium toxicity: a review of neurologic complications. Clin Neuropharmacol 1985;8: 242248.
107.Addonizio, G. Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics. J Clin Psychopharmacol 1985;5: 296298.
108.Velamoor, VR, Swamy, GN, Parmar, RSet al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry 1995;40: 545550.
109.Scheftner, WA, Sculman, RB. Treatment choice in neuroleptic malignant syndrome. Convuls Ther 1992; 8: 267279.
110.Nolen, WA, Zwaan, WA. Treatment of lethal catatonia with electroconvulsive therapy and dantrolene sodium: a case report. Acta Psychiatr Scand 1990;82: 9092.
111.Pennati, A, Sacchetti, E, Calzeroni, A. Dantrolene in lethal catatonia. Am J Psychiatry 1991;148: 268.
112.Kelft, EV, Dehert, M, Heytens, Let al. Management of lethal catatonia with dantrolene sodium. Crit Care Med 1991;19: 14491451.
113.Philbrick, KL, Rummans, TA. Malignant catatonia. J Neuropsychiatry 1994;6: 113.
114.Mann, SC, Caroff, SN, Bleir, HRet al. Electroconvulsive therapy of the lethal catatonia syndrome: case report and review. Convuls Ther 1990; 6: 239247.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed